

Appendix A
Amendments to the Claims

This listing of the claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims

1. **(Currently Amended)** A bispecific molecule comprising an anti-CR1 antibody linked to a non-neutralizing antibody that binds to a bacterial antigen or toxin a pathogenic agent of an animal.

2.-62. **(Cancelled)**

63. **(New)** The bispecific molecule of claim 1, wherein the non-neutralizing antibody binds to Staphylococcal protein A.

64. **(New)** The bispecific molecule of claim 1, wherein the non-neutralizing antibody binds to anthrax protective antigen.

65. **(New)** The bispecific molecule of claim 1, wherein the anti-CR1 antibody is cross-linked to the non-neutralizing antibody.

66. **(New)** The bispecific molecule of claim 1, wherein at least one of the anti-CR1 antibody and the non-neutralizing antibody are monoclonal antibodies.

67. **(New)** The bispecific molecule of claim 1, wherein one or more of the antibodies is modified to reduce its immunogenicity.

68. **(New)** The bispecific molecule of claim 65, wherein one or more of the antibodies is deimmunized.

69. (New) The bispecific molecule of claim 1, wherein one or more of the antibodies is an antigen binding fragment of an antibody.

70. (New) the bispecific molecule of claim 69, wherein the antigen binding fragment is selected from the group consisting of a Fab, Fab', (Fab')₂, Fv, scFv, or scab fragment of an antibody.

71. (New) The bispecific molecule of claim 1, wherein one or more of the antibodies is a full length antibody.

72. (New) The bispecific molecule of claim 63, wherein the anti-CR1 antibody and the non-neutralizing antibody are crosslinked using a crosslinking agent.

73. (New) The bispecific molecule of claim 67, wherein the crosslinking agent is polyethylene glycol (PEG).

74. (New) The bispecific molecule of claim 1, wherein the anti-CR1 antibody is 7G9.

75. (New) The bispecific molecule of claim 1, wherein the anti-CR1 antibody is 19E9.

76. (New) A bispecific molecule comprising an anti-CR1 antibody linked to an antibody that is selected from the group consisting of: 3F3, 2F9, 3F10, 3D2, 16E11, 2C11, 6C3, and an antibody that recognizes *S. aureus* Protein A.